Literature DB >> 22588261

Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor.

Spencer S Ericksen1, David F Cummings, Michael E Teer, Shahnawaz Amdani, John A Schetz.   

Abstract

In an effort to delineate how specific molecular interactions of dopamine receptor ligand classes vary between D2-like dopamine receptor subtypes, a conserved threonine in transmembrane (TM) helix 7 (Thr7.39), implicated as a key ligand interaction site with biogenic amine G protein-coupled receptors, was substituted with alanine in D2 and D4 receptors. Interrogation of different ligand chemotypes for sensitivity to this substitution revealed enhanced affinity in the D4, but not the D2 receptor, specifically for substituted benzamides (SBAs) having polar 4- (para) and/or 5- (meta) benzamide ring substituents. D4-T7.39A was fully functional, and the mutation did not alter the sodium-mediated positive and negative allostery observed with SBAs and agonists, respectively. With the exception of the non-SBA ligand (+)-butaclamol, which, in contrast to certain SBAs, had decreased affinity for the D4-T7.39A mutant, the interactions of numerous other ligands were unaffected by this mutation. SBAs were docked into D4 models in the same mode as observed for eticlopride in the D3 crystal structure. In this mode, interactions with TM5 and TM6 residues constrain the SBA ring position that produces distal steric crowding between pyrrolidinyl/diethylamine moieties and D4-Thr7.39. Ligand-residue interaction energy profiles suggest this crowding is mitigated by substitution with a smaller alanine. The profiles indicate sites that contribute to the SBA binding interaction and site-specific energy changes imparted by the D4-T7.39A mutation. Substantial interaction energy changes are observed at only a few positions, some of which are not conserved among the dopamine receptor subtypes and thus seem to account for this D4 subtype-specific structure-activity relationship.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588261      PMCID: PMC3400798          DOI: 10.1124/jpet.112.193979

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Tandem sulfur-containing amino acids are epicritical determinants of dopamine D(2) receptor pharmacology.

Authors:  J A Schetz; D R Sibley
Journal:  Eur J Pharmacol       Date:  2000-01-28       Impact factor: 4.432

2.  The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation.

Authors:  J A Schetz; D R Sibley
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

3.  A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists.

Authors:  S Suryanarayana; D A Daunt; M Von Zastrow; B K Kobilka
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

4.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments.

Authors:  M M Simpson; J A Ballesteros; V Chiappa; J Chen; M Suehiro; D S Hartman; T Godel; L A Snyder; T P Sakmar; J A Javitch
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  The preclinical pharmacologic profile of tiapride.

Authors:  B Scatton; C Cohen; G Perrault; A Oblin; Y Claustre; H Schoemaker; D J Sanger; L Rouquier; R Porsolt
Journal:  Eur Psychiatry       Date:  2001-01       Impact factor: 5.361

7.  Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Authors:  Jorge D Brioni; Robert B Moreland; Marlon Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

8.  Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors.

Authors:  X M Guan; S J Peroutka; B K Kobilka
Journal:  Mol Pharmacol       Date:  1992-04       Impact factor: 4.436

9.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors.

Authors:  D Oksenberg; S A Marsters; B F O'Dowd; H Jin; S Havlik; S J Peroutka; A Ashkenazi
Journal:  Nature       Date:  1992-11-12       Impact factor: 49.962

10.  A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors.

Authors:  E M Parker; D A Grisel; L G Iben; R A Shapiro
Journal:  J Neurochem       Date:  1993-01       Impact factor: 5.372

View more
  3 in total

1.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; John A Schetz
Journal:  Neurochem Int       Date:  2017-02-08       Impact factor: 3.921

3.  A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus.

Authors:  Valerio Mammoli; Alessandro Bonifazi; Diego Dal Ben; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Maria Pigini; Wilma Quaglia; Ajiroghene Thomas; Amy H Newman; Sergi Ferré; Marta Sanchez-Soto; Thomas M Keck; Fabio Del Bello
Journal:  ChemMedChem       Date:  2016-03-15       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.